Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

  1. Musolino, A.
  2. Campone, M.
  3. Neven, P.
  4. Denduluri, N.
  5. Barrios, C.H.
  6. Cortes, J.
  7. Blackwell, K.
  8. Soliman, H.
  9. Kahan, Z.
  10. Bonnefoi, H.
  11. Squires, M.
  12. Zhang, Y.
  13. Deudon, S.
  14. Shi, M.M.
  15. André, F.
Aldizkaria:
Breast Cancer Research

ISSN: 1465-542X,  1465-5411

Argitalpen urtea: 2017

Alea: 19

Zenbakia: 1

Mota: Artikulua

DOI: 10.1186/S13058-017-0807-8 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus